Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. NRIX
stocks logo

NRIX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
29.35M
+142.74%
-0.712
+0.23%
15.12M
+20.14%
-0.856
+27.77%
13.36M
+0.6%
-0.887
+18.3%
Estimates Revision
The market is revising Upward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by 0.78% over the past three months. During the same period, the stock price has changed by 21.29%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.59%
In Past 3 Month
Stock Price
Go Up
up Image
+21.29%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 29.50 USD with a low forecast of 16.00 USD and a high forecast of 36.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 12.420
sliders
Low
16.00
Averages
29.50
High
36.00
up Image0
Current: 12.420
sliders
Low
16.00
Averages
29.50
High
36.00
Morgan Stanley
Terence Flynn
Equal Weight
downgrade
$17 -> $16
2025-07-15
New
Reason
Morgan Stanley
Terence Flynn
Price Target
$17 -> $16
2025-07-15
New
downgrade
Equal Weight
Reason
Morgan Stanley analyst Terence Flynn lowered the firm's price target on Nurix Therapeutics to $16 from $17 and keeps an Equal Weight rating on the shares. Nurix's pipeline is on track with clinical updates expected in 2H25, while bexobrutideg remains the key driver for the stock, with Nurix increasing investment behind the program, the analyst says.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$36 -> $34
2025-07-14
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$36 -> $34
2025-07-14
New
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Nurix Therapeutics to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm's previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward.
UBS
Buy
downgrade
$30 -> $26
2025-07-10
Reason
UBS
Price Target
$30 -> $26
2025-07-10
downgrade
Buy
Reason
UBS lowered the firm's price target on Nurix Therapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm sees asymmetric upside at the current stock price with multiple data catalysts in the next 12 months, the analyst tells investors in a research note.
Oppenheimer
Matthew Biegler
Outperform
maintain
$32 -> $30
2025-07-10
Reason
Oppenheimer
Matthew Biegler
Price Target
$32 -> $30
2025-07-10
maintain
Outperform
Reason
Oppenheimer analyst Matthew Biegler lowered the firm's price target on Nurix Therapeutics to $30 from $32 and keeps an Outperform rating on the shares after the company reported financials. The firm says it is "getting a bit tired of the myopic argument that the CLL market is a zero-sum game." Historically that's never been the case, says Oppenheimer. Ultimately, the firm sees degraders moving up the pecking order into frontline. By Oppenheimer's estimates, NX-5948 is 6-12 months behind BeOne, but has advantages in safety and efficacy that can be exploited.
Wells Fargo
Derek Archila
Buy
Maintains
$32 → $25
2025-04-09
Reason
Wells Fargo
Derek Archila
Price Target
$32 → $25
2025-04-09
Maintains
Buy
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Nurix Therapeutics to $25 from $32 and keeps an Overweight rating on the shares. The firm views bexobrutideg as highly de-risked in CLL and thinks regulatory updates and initiation of pivotal trials are modest catalysts in 2025. With shares approaching 52-week lows, it offers an attractive entry point for long-term investors, Wells adds.
Stifel
Stephen Willey
Strong Buy
Maintains
$36 → $35
2025-04-09
Reason
Stifel
Stephen Willey
Price Target
$36 → $35
2025-04-09
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nurix Therapeutics Inc (NRIX.O) is -3.42, compared to its 5-year average forward P/E of -6.81. For a more detailed relative valuation and DCF analysis to assess Nurix Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.81
Current PE
-3.42
Overvalued PE
-2.46
Undervalued PE
-11.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.57
Current EV/EBITDA
-2.02
Overvalued EV/EBITDA
-0.16
Undervalued EV/EBITDA
-8.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
19.79
Current PS
15.78
Overvalued PS
32.59
Undervalued PS
6.99

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NRIX News & Events

Events Timeline

(ET)
2025-07-09
16:04:32
Nurix Therapeutics reports Q2 EPS (52c), consensus (74c)
select
2025-07-07 (ET)
2025-07-07
07:02:12
Nurix announces EMA grant of Orphan Drug Designation for bexobrutideg
select
2025-06-12 (ET)
2025-06-12
07:11:33
Nurix Therapeutics presents updated data from ongoing trial of bexobrutideg
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-15Benzinga
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts
  • Analyst Ratings Overview: Nurix Therapeutics has received mixed ratings from analysts, with a total of 5 ratings reflecting a combination of bullish and bearish sentiments, alongside a recent average price target decrease to $29.4 from $31.0.

  • Financial Performance Insights: The company shows strong revenue growth of 264.34% but has a negative net margin of -98.66%, indicating challenges in profitability despite effective debt management and a solid return on equity.

Preview
4.0
07-12TipRanks
Top 3 Trending Stocks, According to Analysts – 7/11/2025
  • Trending Stocks Overview: TipRanks has identified the top three most-rated stocks in the past 72 hours, including Ultragenyx Pharmaceutical (RARE), Rhythm Pharmaceuticals (RYTM), and Nurix Therapeutics (NRIX), all receiving strong buy ratings from analysts with significant potential upside.

  • Smart Portfolio Tool: The TipRanks Smart Portfolio provides insights for investors by analyzing their stock holdings, comparing portfolios, and offering AI-generated explanations for stock movements, making it easier to make informed investment decisions.

Preview
6.0
07-11NASDAQ.COM
New Analyst Forecast: $NRIX Given $26.0 Price Target
  • Analyst Forecasts: David Dai from UBS has set a price target of $26.0 for $NRIX, with a median target of $27.0 from 11 analysts over the past 6 months.

  • Insider Trading and Institutional Activity: In the last 6 months, $NRIX insiders have sold shares 14 times without any purchases, while 89 institutional investors increased their holdings and 80 decreased theirs in the latest quarter.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nurix Therapeutics Inc (NRIX) stock price today?

The current price of NRIX is 12.42 USD — it has increased 2.22 % in the last trading day.

arrow icon

What is Nurix Therapeutics Inc (NRIX)'s business?

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

arrow icon

What is the price predicton of NRIX Stock?

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 29.50 USD with a low forecast of 16.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nurix Therapeutics Inc (NRIX)'s revenue for the last quarter?

Nurix Therapeutics Inc revenue for the last quarter amounts to 44.06M USD, increased 264.34 % YoY.

arrow icon

What is Nurix Therapeutics Inc (NRIX)'s earnings per share (EPS) for the last quarter?

Nurix Therapeutics Inc. EPS for the last quarter amounts to -0.52 USD, decreased -26.76 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nurix Therapeutics Inc (NRIX)'s fundamentals?

The market is revising Upward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by 0.78% over the past three months. During the same period, the stock price has changed by 21.29%.
arrow icon

How many employees does Nurix Therapeutics Inc (NRIX). have?

Nurix Therapeutics Inc (NRIX) has 286 emplpoyees as of July 17 2025.

arrow icon

What is Nurix Therapeutics Inc (NRIX) market cap?

Today NRIX has the market capitalization of 949.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free